Bicyclic heteroaryl derivatives and preparation and uses thereof
The present invention relates compounds of Formula (A), as well as their preparation and uses, and further relates pharmaceutical compositions comprising these compounds and their uses as modulators of dysfunctional glutamate transmission. The present invention also relates to uses of the compounds or pharmaceutical compositions in treating or preventing certain neurological and psychiatric disorders and diseases as well as cancer in humans.
1. The compound 6-(pentafluoro-λ 6 -sulfaneyl)benzo[d]thiazol-2-amine (I):
or a pharmaceutically acceptable salt thereof.
2. The compound 6-(pentafluoro-λ 6 -sulfaneyl)benzo[d][1,3]selenazol-2-amine (V):
or a pharmaceutically acceptable salt thereof.
3. The compound 6-(trifluoromethyl)benzo[d][1,3]selenazol-2-amine (VI):
or a pharmaceutically acceptable salt thereof.
4. The compound 6-((trifluoromethyl)thio)benzo[d][1,3]selenazol-2-amine (IX):
or a pharmaceutically acceptable salt thereof.
5. A pharmaceutical composition comprising:
a therapeutically effective amount of the compound of claim 1 or a pharmaceutically acceptable salt thereof; and
a pharmaceutically acceptable excipient, carrier, adjuvant, solvent, or a combination of any of the foregoing.
6. The pharmaceutical composition of claim 5 , wherein the pharmaceutical composition is a transdermal formulation.
7. The pharmaceutical composition of claim 5 , wherein the pharmaceutical composition is an oral formulation.
8. A pharmaceutical composition comprising:
a therapeutically effective amount of the compound of claim 2 or a pharmaceutically acceptable salt thereof; and
a pharmaceutically acceptable excipient, carrier, adjuvant, solvent, or a combination of any of the foregoing.
9. The pharmaceutical composition of claim 8 , wherein the pharmaceutical composition is a transdermal formulation.
10. The pharmaceutical composition of claim 8 , wherein the pharmaceutical composition is an oral formulation.
11. A pharmaceutical composition comprising:
a therapeutically effective amount of the compound of claim 3 or a pharmaceutically acceptable salt thereof; and
a pharmaceutically acceptable excipient, carrier, adjuvant, solvent, or a combination of any of the foregoing.
12. The pharmaceutical composition of claim 11 , wherein the pharmaceutical composition is a transdermal formulation.
13. The pharmaceutical composition of claim 11 , wherein the pharmaceutical composition is an oral formulation.
14. A pharmaceutical composition comprising:
a therapeutically effective amount of the compound of claim 4 or a pharmaceutically acceptable salt thereof; and
a pharmaceutically acceptable excipient, carrier, adjuvant, solvent, or a combination of any of the foregoing.
15. The pharmaceutical composition of claim 14 , wherein the pharmaceutical composition is a transdermal formulation.
16. The pharmaceutical composition of claim 14 , wherein the pharmaceutical composition is an oral formulation.